Discovery of potent LPA2 (EDG4) antagonists as potential anticancer agents

被引：39

作者：

Beck, Hilary P. ^{[1
]}

Kohn, Todd ^{[1
]}

Rubenstein, Steven ^{[1
]}

Hedberg, Christine ^{[1
]}

Schwandner, Ralf ^{[2
]}

Hasslinger, Kerstin ^{[2
]}

Dai, Kang ^{[1
]}

Li, Cong ^{[1
]}

Liang, Lingining ^{[1
]}

Wesche, Holger ^{[1
]}

Frank, Brendon ^{[1
]}

An, Songhzu ^{[1
]}

Wckramasinghe, Dineli ^{[1
]}

Jaen, Juan ^{[1
]}

Medina, Julio ^{[1
]}

Hungate, Randall ^{[1
]}

Shen, Wang ^{[1
]}

机构：

[1] Amgen Inc, Chem Res & Discovery, San Francisco, CA 94080 USA

[2] Amgen Res GmbH, Chem Res & Discovery, Regensburg, Germany

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2008年 / 18卷 / 03期

关键词：

LPA2; EDG4; LPA; anticancer agents;

D O I：

10.1016/j.bmcl.2007.12.024

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

The LPA(2) protein is overexpressed in many tumor cells. We report the optimization of a series of LPA(2) antagonists using calcium mobilization assay (aequorin assay) that led to the discovery of the first reported inhibitors selective for LPA(2). Key compounds were evaluated in vitro for inhibition of LPA(2) mediated Erk activation and proliferation of HCT-116 cells. These compounds could be used to evaluate the benefits of LPA(2) inhibition both in vitro and in vivo. (C) 2007 Elsevier Ltd. All rights reserved.

引用

页码：1037 / 1041

页数：5

共 20 条

[1] Recombinant human G protein-coupled lysophosphatidic acid receptors mediate intracellular calcium mobilization [J].

An, SZ ;

Bleu, T ;

Zheng, YH ;

Goetzl, EJ .

MOLECULAR PHARMACOLOGY, 1998, 54 (05) :881-888

[2] Molecular cloning and characterization of a novel human G-protein-coupled receptor, EDG7, for lysophosphatidic acid [J].

Bandoh, K ;

Aoki, J ;

Hosono, H ;

Kobayashi, S ;

Kobayashi, T ;

Murakami-Murofushi, K ;

Tsujimoto, M ;

Arai, H ;

Inoue, K .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (39) :27776-27785

[3] Up-regulation of interleukin-6 in human ovarian cancer cell via a Gi/PI3K-Akt/NF-κB pathway by lysophosphatidic acid, an ovarian cancer-activating factor [J].

Chou, CH ;

Wei, LH ;

Huang, YJ ;

Lai, KP ;

Chen, CA ;

Hsieh, CY .

CARCINOGENESIS, 2005, 26 (01) :45-52

[4] International Union of Pharmacology. XXXIV. Lysophospholipid receptor nomenclature [J].

Chun, J ;

Goetzl, EJ ;

Hla, T ;

Igarashi, Y ;

Lynch, KR ;

Moolenaar, W ;

Pyne, S ;

Tigyi, G .

PHARMACOLOGICAL REVIEWS, 2002, 54 (02) :265-269

[5] Lysophosphatidic acid receptors [J].

Contos, JJA ;

Ishii, I ;

Chun, J .

MOLECULAR PHARMACOLOGY, 2000, 58 (06) :1188-1196

[6]

Estrella VC, 2007, INT J ONCOL, V31, P441

[7] α-substituted phosphonate analogues of lysophosphatidic acid (LPA) selectively inhibit production and action of LPA [J].

Jiang, Guowei ;

Xu, Yong ;

Fujiwara, Yuko ;

Tsukahara, Tamotsu ;

Tsukahara, Ryoko ;

Gajewiak, Joanna ;

Tigyi, Gabor ;

Prestwich, Glenn D. .

CHEMMEDCHEM, 2007, 2 (05) :679-690

[8] Over-expression of lysophosphatidic acid receptor-2 in human invasive ductal carcinoma [J].

Kitayama, J ;

Shida, D ;

Sako, A ;

Ishikawa, M ;

Hama, K ;

Aoki, J ;

Arai, H ;

Nagawa, H .

BREAST CANCER RESEARCH, 2004, 6 (06) :R640-R646

[9] Identification of an intracellular receptor for lysophosphatidic acid (LPA):: LPA is a transcellular PPARγ agonist [J].

McIntyre, TM ;

Pontsler, AV ;

Silva, AR ;

St Hilaire, A ;

Xu, Y ;

Hinshaw, JC ;

Zimmerman, GA ;

Hama, K ;

Aoki, J ;

Arai, H ;

Prestwich, GD .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (01) :131-136

[10]

MILLS GB, 2002, CANC TREAT RES, V107, P259

← 1 2 →